Buyer Name: NHS England
Buyer Address: Wellington House, 133-135 Waterloo Rd, London, UKI45, SE1 8UG, United Kingdom
Contact Name: Balram Kullootee
Contact Email: b.kullootee@nhs.net
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
Buyer Contact Info
Status
complete
complete
Procedure
open
open
Value
688834174.0 GBP
688834174.0 GBP
Published
06 Oct 2025, 11:40
06 Oct 2025, 11:40
Deadline
n/a
n/a
Contract Start
01 Dec 2025, 00:00
01 Dec 2025, 00:00
Contract End
31 May 2027, 22:59
31 May 2027, 22:59
Category
n/a
n/a
CPV
33600000 - Pharmaceutical products
33600000 - Pharmaceutical products
Region
n/a
n/a
Awarded To
Abbvie Ltd, Alimera Sciences, Bayer Plc, Biogen, Novartis Pharmaceuticals UK Ltd, Orion Pharma (UK) Ltd, Outlook Therapeutics, Inc., Roche Products Ltd, Teva UK Limited, Thornton and Ross Ltd, BIOSIMILAR COLLABORATIONS IRELAND LIMITED, Celltrion Healthcare United Kingdom Limited, MDBIOLOGICS LTD, SANDOZ LIMITED
Abbvie Ltd, Alimera Sciences, Bayer Plc, Biogen, Novartis Pharmaceuticals UK Ltd, Orion Pharma (UK) Ltd, Outlook Therapeutics, Inc., Roche Products Ltd, Teva UK Limited, Thornton and Ross Ltd, BIOSIMILAR COLLABORATIONS IRELAND LIMITED, Celltrion Healthcare United Kingdom Limited, MDBIOLOGICS LTD, SANDOZ LIMITED
Official Source
Open Find a Tender
Open Find a Tender
Description
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 Offer reference number: CM/PHS/25/5728 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National) 01/12/2025 to 31/05/2027 (18 months) CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg: NOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months) SOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months) MAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months) LNW: (London) 01/12/2025 to 31/05/2027 (18 months) Published By: Medicines Procurement and Supply Chain – NHS Medicines Value & Access, NHS England Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
Linked Documents
Select a document to preview.
Opportunity Context
Lots
Lot 1 Status: complete
Documents
Document Description: Not published
Contracts
Contract Title: Lot 1 - CM/PHS/25/5728/01
Contract Title: Lot 2 - CM/PHS/25/5728/02
Raw Notice JSON
Expand raw payload
{
"awards": [
{
"id": "2",
"items": [
{
"additionalClassifications": [
{
"description": "Pharmaceutical products",
"id": "33600000",
"scheme": "CPV"
}
],
"id": "1",
"relatedLot": "1"
}
],
"mainProcurementCategory": "goods",
"relatedLots": [
"1"
],
"status": "active",
"suppliers": [
{
"id": "GB-PPON-PHRQ-1133-WGCH",
"name": "Abbvie Ltd"
},
{
"id": "GB-PPON-PYCZ-7339-TCCT",
"name": "Alimera Sciences"
},
{
"id": "GB-COH-00935048",
"name": "Bayer Plc"
},
{
"id": "GB-PPON-PTGT-3385-PBMQ",
"name": "Biogen"
},
{
"id": "GB-PPON-PJTX-5182-QVLR",
"name": "Novartis Pharmaceuticals UK Ltd"
},
{
"id": "GB-PPON-PJZQ-1429-ZBVY",
"name": "Orion Pharma (UK) Ltd"
},
{
"id": "GB-PPON-PGZH-1763-NPGX",
"name": "Outlook Therapeutics, Inc."
},
{
"id": "GB-PPON-PXCG-4172-CHYM",
"name": "Roche Products Ltd"
},
{
"id": "GB-PPON-PWDD-6894-DXRM",
"name": "Teva UK Limited"
},
{
"id": "GB-PPON-PWYH-6892-QYNN",
"name": "Thornton and Ross Ltd"
}
]
},
{
"id": "3",
"items": [
{
"additionalClassifications": [
{
"description": "Pharmaceutical products",
"id": "33600000",
"scheme": "CPV"
}
],
"id": "1",
"relatedLot": "1"
}
],
"mainProcurementCategory": "goods",
"relatedLots": [
"1"
],
"status": "active",
"suppliers": [
{
"id": "GB-PPON-PWRY-2527-LDRY",
"name": "Bayer Plc"
},
{
"id": "GB-PPON-PQQC-5869-LMVX",
"name": "BIOSIMILAR COLLABORATIONS IRELAND LIMITED"
},
{
"id": "GB-PPON-PYQL-4248-PXXY",
"name": "Celltrion Healthcare United Kingdom Limited"
},
{
"id": "GB-PPON-PMHC-1596-RTNX",
"name": "MDBIOLOGICS LTD"
},
{
"id": "GB-PPON-PNQL-1548-CYBZ",
"name": "SANDOZ LIMITED"
}
]
}
],
"buyer": {
"id": "GB-PPON-PDPT-3135-BWWY",
"name": "NHS England"
},
"contracts": [
{
"aboveThreshold": true,
"agreedMetrics": [
{
"description": "6 months Buffer Stock",
"id": "1",
"observations": [
{
"id": "frequency",
"period": {
"durationInMonths": 3
}
}
],
"title": "Buffer Stock requirement"
}
],
"awardID": "2",
"dateSigned": "2025-09-22T00:00:00+01:00",
"documents": [
{
"description": "Framework Agreement and Terms and Conditions - Lot 1",
"documentType": "contractSigned",
"format": "application/pdf",
"id": "A-5896",
"url": "https://www.find-tender.service.gov.uk/Notice/Attachment/A-5896"
},
{
"datePublished": "2025-10-06T12:40:50+01:00",
"description": "Contract details notice on Find a Tender",
"documentType": "contractNotice",
"format": "text/html",
"id": "062482-2025",
"noticeType": "UK7",
"url": "https://www.find-tender.service.gov.uk/Notice/062482-2025"
}
],
"hasRenewal": true,
"id": "2",
"period": {
"endDate": "2027-05-31T23:59:59+01:00",
"maxExtentDate": "2029-05-31T23:59:59+01:00",
"startDate": "2025-12-01T00:00:00Z"
},
"renewal": {
"description": "option or options to extend (at the discretion of the Authority) up to maximum of 24 months."
},
"status": "active",
"title": "Lot 1 - CM/PHS/25/5728/01",
"value": {
"amount": 688834174.0,
"amountGross": 826601009.0,
"currency": "GBP"
}
},
{
"aboveThreshold": true,
"agreedMetrics": [
{
"description": "6 months Buffer Stock",
"id": "1",
"observations": [
{
"id": "frequency",
"period": {
"durationInMonths": 3
}
}
],
"title": "Buffer Stock"
}
],
"awardID": "3",
"dateSigned": "2025-09-22T00:00:00+01:00",
"documents": [
{
"description": "Framework Agreement and Terms and Conditions - Lot 2",
"documentType": "contractSigned",
"format": "application/pdf",
"id": "A-5897",
"url": "https://www.find-tender.service.gov.uk/Notice/Attachment/A-5897"
},
{
"datePublished": "2025-10-06T12:40:50+01:00",
"description": "Contract details notice on Find a Tender",
"documentType": "contractNotice",
"format": "text/html",
"id": "062482-2025",
"noticeType": "UK7",
"url": "https://www.find-tender.service.gov.uk/Notice/062482-2025"
}
],
"hasRenewal": true,
"id": "3",
"period": {
"endDate": "2027-05-31T23:59:59+01:00",
"maxExtentDate": "2029-05-31T23:59:59+01:00",
"startDate": "2025-12-01T00:00:00Z"
},
"renewal": {
"description": "option or options to extend (at the discretion of the Authority) up to maximum of 24 months."
},
"status": "active",
"title": "Lot 2 - CM/PHS/25/5728/02",
"value": {
"amount": 782917972.0,
"amountGross": 939501566.0,
"currency": "GBP"
}
}
],
"date": "2025-10-06T12:40:50+01:00",
"id": "062482-2025",
"initiationType": "tender",
"language": "en",
"ocid": "ocds-h6vhtk-055064",
"parties": [
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "SE1 8UG",
"region": "UKI45",
"streetAddress": "Wellington House, 133-135 Waterloo Rd"
},
"contactPoint": {
"email": "b.kullootee@nhs.net",
"name": "Balram Kullootee"
},
"details": {
"classifications": [
{
"description": "Public authority - central government",
"id": "publicAuthorityCentralGovernment",
"scheme": "UK_CA_TYPE"
}
],
"url": "https://www.england.nhs.uk/"
},
"id": "GB-PPON-PDPT-3135-BWWY",
"identifier": {
"id": "PDPT-3135-BWWY",
"scheme": "GB-PPON"
},
"name": "NHS England",
"roles": [
"buyer"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Maidenhead",
"postalCode": "SL6 4UB",
"region": "UKJ11",
"streetAddress": "Abbvie House Vanwall Business Park"
},
"contactPoint": {
"email": "val.stenning@abbvie.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PHRQ-1133-WGCH",
"identifier": {
"id": "PHRQ-1133-WGCH",
"scheme": "GB-PPON"
},
"name": "Abbvie Ltd",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Hook",
"postalCode": "RG27 9XA",
"region": "UKJ37",
"streetAddress": "Form 1 Bartley Wood Business Park"
},
"contactPoint": {
"email": "catherine.griffiths@alimerasciences.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PYCZ-7339-TCCT",
"identifier": {
"id": "PYCZ-7339-TCCT",
"scheme": "GB-PPON"
},
"name": "Alimera Sciences",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Reading",
"postalCode": "RG26AD",
"region": "UKJ11",
"streetAddress": "400 South Oak Way"
},
"contactPoint": {
"email": "andrew.asbury@bayer.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-COH-00935048",
"identifier": {
"id": "00935048",
"scheme": "GB-COH"
},
"name": "Bayer Plc",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Maidenhead",
"postalCode": "SL63UD",
"region": "UKJ11",
"streetAddress": "Building 5 Foundation Park"
},
"contactPoint": {
"email": "bbumarketaccessuk@biogen.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PTGT-3385-PBMQ",
"identifier": {
"id": "PTGT-3385-PBMQ",
"scheme": "GB-PPON"
},
"name": "Biogen",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "W12 7FQ",
"region": "UKI33",
"streetAddress": "2nd Floor, The Westworks Building White City Place"
},
"contactPoint": {
"email": "commercial.team@novartis.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PJTX-5182-QVLR",
"identifier": {
"id": "PJTX-5182-QVLR",
"scheme": "GB-PPON"
},
"name": "Novartis Pharmaceuticals UK Ltd",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "EC3M 7AF",
"region": "UKI31",
"streetAddress": "The Scalpel, 18th Floor"
},
"contactPoint": {
"email": "mark.soderberg@orionpharma.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "sme",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PJZQ-1429-ZBVY",
"identifier": {
"id": "PJZQ-1429-ZBVY",
"scheme": "GB-PPON"
},
"name": "Orion Pharma (UK) Ltd",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Surrey",
"postalCode": "GU1 1UN",
"region": "UKJ25",
"streetAddress": "3rd Floor One London Square, Cross Lanes, Guildford,"
},
"contactPoint": {
"email": "uktenders@outlooktherapeutics.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "sme",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PGZH-1763-NPGX",
"identifier": {
"id": "PGZH-1763-NPGX",
"scheme": "GB-PPON"
},
"name": "Outlook Therapeutics, Inc.",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Welwyn Garden City",
"postalCode": "AL7 1TW",
"region": "UKH23",
"streetAddress": "6 Falcon Way"
},
"contactPoint": {
"email": "welwyn.rx_bdop@roche.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PXCG-4172-CHYM",
"identifier": {
"id": "PXCG-4172-CHYM",
"scheme": "GB-PPON"
},
"name": "Roche Products Ltd",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Castleford",
"postalCode": "WF10 5HX",
"region": "UKE45",
"streetAddress": "Ridings Point"
},
"contactPoint": {
"email": "chrissie.kellett@tevauk.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PWDD-6894-DXRM",
"identifier": {
"id": "PWDD-6894-DXRM",
"scheme": "GB-PPON"
},
"name": "Teva UK Limited",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Huddersfield",
"postalCode": "HD7 5QH",
"region": "UKE44",
"streetAddress": "Linthwaite Labs Manchester Road"
},
"contactPoint": {
"email": "rachelwright@thorntonross.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PWYH-6892-QYNN",
"identifier": {
"id": "PWYH-6892-QYNN",
"scheme": "GB-PPON"
},
"name": "Thornton and Ross Ltd",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Reading",
"postalCode": "RG2 6AD",
"region": "UKJ11",
"streetAddress": "400 South Oak Way"
},
"contactPoint": {
"email": "andrew.asbury@bayer.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PWRY-2527-LDRY",
"identifier": {
"id": "PWRY-2527-LDRY",
"scheme": "GB-PPON"
},
"name": "Bayer Plc",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "WC2B 5AH",
"region": "UKI31",
"streetAddress": "Biocon Biologics 16 Great Queen Street"
},
"contactPoint": {
"email": "uk_tenders@biocon.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PQQC-5869-LMVX",
"identifier": {
"id": "PQQC-5869-LMVX",
"scheme": "GB-PPON"
},
"name": "BIOSIMILAR COLLABORATIONS IRELAND LIMITED",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Uxbridge",
"postalCode": "UB8 1JG",
"region": "UKI74",
"streetAddress": "Celltrion Healthcare UK Limited, The Charter Building, Charter Place"
},
"contactPoint": {
"email": "james.potter@celltrionhc.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PYQL-4248-PXXY",
"identifier": {
"id": "PYQL-4248-PXXY",
"scheme": "GB-PPON"
},
"name": "Celltrion Healthcare United Kingdom Limited",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "London",
"postalCode": "WC2H 9JQ",
"region": "UKI31",
"streetAddress": "71-75 Shelton Street"
},
"contactPoint": {
"email": "paul.clark@mdbiologics.co.uk"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "sme",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PMHC-1596-RTNX",
"identifier": {
"id": "PMHC-1596-RTNX",
"scheme": "GB-PPON"
},
"name": "MDBIOLOGICS LTD",
"roles": [
"supplier"
]
},
{
"address": {
"country": "GB",
"countryName": "United Kingdom",
"locality": "Bracknell",
"postalCode": "RG12 1RF",
"region": "UKJ11",
"streetAddress": "Maxis 1, Western Road"
},
"contactPoint": {
"email": "uk.hosp@sandoz.com"
},
"details": {
"publicServiceMissionOrganization": false,
"scale": "large",
"shelteredWorkshop": false,
"vcse": false
},
"id": "GB-PPON-PNQL-1548-CYBZ",
"identifier": {
"id": "PNQL-1548-CYBZ",
"scheme": "GB-PPON"
},
"name": "SANDOZ LIMITED",
"roles": [
"supplier"
]
}
],
"tag": [
"award",
"contract"
],
"tender": {
"description": "NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 \nOffer reference number: CM/PHS/25/5728\nPeriod of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months.\nPotential periods of call-offs under the framework agreement:\nCM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments:\n7NAT (National) 01/12/2025 to 31/05/2027 (18 months)\nCM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg:\nNOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months) \nSOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months) \nMAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months)\nLNW: (London) 01/12/2025 to 31/05/2027 (18 months)\nPublished By: Medicines Procurement and Supply Chain \u2013 NHS Medicines Value \u0026 Access, NHS England \nProvision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; \n\u2022 neovascular (wet) age-related macular degeneration (AMD)\n\u2022 visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)\n\u2022 proliferative diabetic retinopathy (PDR)\n\u2022 visual impairment due to diabetic macular oedema (DME) \n\u2022 visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy\n\u2022 vision impairment associated with chronic diabetic macular oedema, (DME)\n\u2022 visual impairment due to myopic choroidal neovascularisation (myopic CNV) \n\u2022 retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease\n\u2022 inflammation of the posterior segment of the eye presenting as non-infectious uveitis\n\u2022 prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye",
"documents": [
{
"description": "Not published",
"documentType": "conflictOfInterest",
"id": "conflictOfInterest"
}
],
"id": "C346388",
"legalBasis": {
"id": "2023/54",
"scheme": "UKPGA",
"uri": "https://www.legislation.gov.uk/ukpga/2023/54/contents"
},
"lots": [
{
"id": "1",
"status": "complete"
}
],
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"status": "complete",
"techniques": {
"frameworkAgreement": {
"buyerCategories": "Please refer to Document No. 09 in the ITO Documents for the list of Purchasing Points",
"buyerLocationRestrictions": [
{
"gazetteer": {
"identifiers": [
"UK"
],
"scheme": "GB-ITL"
}
}
],
"description": "Please refer to the ITO Documents for the Operation Description.",
"method": "withoutReopeningCompetition",
"type": "open"
},
"hasFrameworkAgreement": true
},
"title": "NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025"
}
}